A pilot, pharmacokinetic (PK), and pharmacodynamic (PD) study to determine the feasibility of intrapatient dose escalation to tolerable rash and the activity of maximal doses of erlotinib (E) in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Autor:	S. Yancik, C. A. Mita, M.J.A. de Jonge, M. Hamilton, P. Santabarbara, Leslie Wood, Garry Schwartz, E. K. Rowinsky, Monica M. Mita, Kyriakos P. Papadopoulos
Rok vydání:	2005
Předmět:	Cancer Research business.industry medicine.drug_class non-small cell lung cancer (NSCLC) Pharmacology medicine.disease Rash Tyrosine-kinase inhibitor Oncology Pharmacokinetics Growth factor receptor Pharmacodynamics medicine Dose escalation Erlotinib medicine.symptom business medicine.drug
Zdroj:	Journal of Clinical Oncology. 23:3045-3045
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2005.23.16_suppl.3045
Popis:	3045 Background: The recommended dose of the epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor E may have been based in part on skin rash grade, which may not reflect maximal toler...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0e9ff104626fc98865555f54bc505d9b https://doi.org/10.1200/jco.2005.23.16_suppl.3045 Zobrazit plný text záznamu